Cantargia AB (FNSTO: CANTA) on Wednesday reported earnings after financial items of a negative SEK7,926,000, or SEK0.45 per share, for the second quarter of 2016, from 1 April 2016 to 30 June 2016.

This was a decline over negative earnings after financial items of SEK5,432,000, or SEK0.41 per share, in the second quarter of 2015.

Other operating revenues for the quarter were nil, the same as that reported in the same period a year ago.

Also, during the quarter, the exercise period for warrants of series TO 1 and TO 3 began on 23 March 2016 and ended on 13 April 2016. In total, 4,127,260 warrants of both series were exercised, representing around 83.5% of the number of warrants issued. Reportedly, through the warrants Cantargia raised approximately SEK31.4m, before issue costs.

Cantargia, which operates as a biopharmaceutical company, specialises in the development of antibody-based therapeutics for the treatment of leukaemia and malignant melanomas. Cantargia markets its therapies internationally.

(EUR1.00=SEK9.47)